EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.). Watch their discussion below or on Dr. Sophia’s website.
Andrew Satz on the ‘Amplifying Scientific Innovation’ Podcast with Dr. Sophia Ononye-Onyia
Jul 17, 2020 | Blog | 0 comments
Daniel Gigante
← How Our Algorithm Models the Drug Discovery Process
EVQLV CEO's Article Published in 'Life Science Leader' →
NY Bio-Computation Startup EVQLV Closes Financing Round
by Alexander Sonneborn | February 8, 2021 | Press Releases | 0 Comments
NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...
EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn
by EVQLV | February 1, 2021 | News | 0 Comments
NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...
EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation
by Alexander Sonneborn | January 12, 2021 | Press Releases | 0 Comments
NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...
Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo
by Alexander Sonneborn | December 16, 2020 | Press Releases | 0 Comments
NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...
EVQLV Accepted to Prestigious Techstars Boston Accelerator
by EVQLV | November 18, 2020 | News | 0 Comments
NEW YORK, November 18, 2020 -- EVQLV, a New York company that uses AI to accelerate the development of antibodies, will be one of 10 startups in the new class of the Techstars Boston program. This year’s program will be 100% virtual and, for the first time, will...
0 Comments